BAYRY News
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.
Zacks
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.
Zacks
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
Zacks
NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido
Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.
Zacks
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?
Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Zacks
FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia
Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.
Zacks
Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC
BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.
Zacks
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.
Zacks
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.
Zacks
EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal
EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.
Zacks